Handa Pharmaceuticals (ROCO:6620) EV-to-EBIT : 19.17 (As of May. 30, 2025)

Handa Pharmaceuticals EV-to-EBIT Chart

Handa Pharmaceuticals Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
EV-to-EBIT		Get a 7-Day Free Trial					-8.09	-31.15	-368.57	29.57	18.17

Handa Pharmaceuticals Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial															27.99	29.57	28.15	20.86	18.17

Competitive Comparison of Handa Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Handa Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Handa Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Handa Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Handa Pharmaceuticals's EV-to-EBIT falls into.

Handa Pharmaceuticals EV-to-EBIT Calculation

Handa Pharmaceuticals's EV-to-EBIT for today is calculated as:

Handa Pharmaceuticals's current Enterprise Value is NT$11,256.9 Mil.
Handa Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$587.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Handa Pharmaceuticals  (ROCO:6620) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Handa Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Handa Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2024 was NT$8,716.4 Mil.
Handa Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$587.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Handa Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Handa Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Handa Pharmaceuticals Business Description